Enter multiple symbols separated by commas

Novartis Leukemia Drug Works for Five Years, Study Says

Swiss drugmaker Novartis' cancer-fighting drug Gleevec can still help treat chronic myeloid leukemia even after five years of use, a new study showed on Wednesday.

The long-term study found that 89 percent of more than 500 volunteers who started taking the drug -- also known by the generic name imatinib -- for chronic myeloid leukemia (CML) beginning around June 2000 remained alive.

That survival rate includes all causes of death, according to the study published in The New England Journal of Medicine.

"If you look at CML-specific deaths, the rate is five%," said Brian Druker of the Oregon Health & Science University, who led the study.

"That's truly extraordinary when you think back five years ago when survival rates were less than 50 percent for this disease and we told patients they were lucky if they made it five years. Now we're saying it's more like 95% they will be alive at five years."

The researchers also found very few patients -- just 17% -- developed resistance to the drug over the five-year span.

The other remarkable feature is the risk of relapse is decreasing over time," Druker told Reuters. "That means to me that long-term survival is very likely."

The drug was the first anti-cancer medicine to be designed based on precise knowledge of how a particular cancer grows. It works by blocking a protein known as tyrosine kinase.

But it isn't effective in all cases, and other companies as as well as Novartis have been developing alternatives.

CML is relatively rare. In the United States, it strikes about 4,600 people a year.

The drug has also been approved for other rare forms of leukemia.

In October, Novartis warned Gleevec could, in rare instances, damage the heart. But in the long-term study, drug-related congestive heart failure was seen in only one patient.

The drug has been on the market since 2001.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Monopoly board game turns 80.

    Toy maker Hasbro is bringing the Monopoly board game to the silver screen, in a movie about a boy's quest to make his fortune and avoid jail time.

  • Golfer Phil Mickelson is the "unnamed gambling client" mentioned in a plea agreement taken by another man charged in a money laundering case, sources said.

  • “The Mystery of Capital” author Hernando DeSoto (center) displaying layers of land titles that can be consolidated into a few lines of code on the block chain.  With Bill Tai (left) and George Kikvadze, vice chairman of BitFury (right).

    Venture capitalist Bill Tai has a knack for spotting hot new start-ups. Want to think like him? Check out his summer reading list.

U.S. Video

  • Adam Bain most likely for TWTR: Pro

    Twitter shares are trading lower today as co-founder Jack Dorsey takes over as interim CEO. Eric Jackson, Ironfire Capital, discusses Twitter's next moves and what can get shares moving higher.

  • Greece doesn't matter, could be buy opportunity: Pro

    Dan Greenhaus, BTIG's Chief Global Strategist, weighs in on the latest market action and possible outcomes from Greece.

  • Cashin says: Tsipras overplayed his hand

    CNBC's Bob Pisani and Art Cashin, of UBS, discuss Greek Prime Minister Alexis Tsipras' failed attempt to reach a debt agreement with the IMF and weigh in on what investors should be watching ahead of the July 4th weekend.